Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Centre Oscar Lambret
Ocellaris Pharma, Inc.
NRG Oncology
Astellas Pharma Inc
Dana-Farber Cancer Institute
Actym Therapeutics, Inc.
Institut du Cancer de Montpellier - Val d'Aurelle
Day One Biopharmaceuticals, Inc.
Bristol-Myers Squibb
G1 Therapeutics, Inc.
Telix Pharmaceuticals (Innovations) Pty Limited
University of Chicago
Elevation Oncology
Seagen Inc.
Sotio Biotech Inc.
SWOG Cancer Research Network
Shanghai PerHum Therapeutics Co., Ltd.
Istari Oncology, Inc.
AstraZeneca
Merck Sharp & Dohme LLC
Taris Biomedical LLC
Altor BioScience
ADC Therapeutics S.A.
UroGen Pharma Ltd.
Sumitomo Pharma America, Inc.
Cedars-Sinai Medical Center
Pfizer
Pfizer
The University of Texas Health Science Center at San Antonio
University of Texas Southwestern Medical Center
Fusion Pharmaceuticals Inc.
SCRI Development Innovations, LLC
Hoosier Cancer Research Network
pharmaand GmbH
M.D. Anderson Cancer Center
Canadian Cancer Trials Group
Genmab
pharmaand GmbH
Bristol-Myers Squibb
4D pharma plc
Bristol-Myers Squibb
Xennials Therapeutics Australia Pty Ltd
Wake Forest University Health Sciences
H. Lee Moffitt Cancer Center and Research Institute
Hoosier Cancer Research Network
Istituto Clinico Humanitas
University Hospital, Bordeaux
University Health Network, Toronto
Sir Mortimer B. Davis - Jewish General Hospital